Category Archives: Management of complications & side effects

Complications of myeloma and its treatments

Immunoglobulin A nephropathy in a patient with IgG kappa light-chain myeloma. Chandra A et al. Saudi J Kidney Dis Transpl. 2017 Jul-Aug;28(4):937-941. Priapism with penile gangrene: An unusual presentation of multiple myeloma. Panwar VK et al. Indian J Urol. 2017 Jul-Sep;33(3):251-252. doi: 10.4103/iju.IJU_41_17. Increased corneal densitometry as a subclinical corneal change associated with multiple myeloma. Busch C et al. Eye (Lond). 2017 Jul 14. doi: 10.1038/eye.2017.132. [Epub…

Complications of myeloma and its treatments

Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R et al. Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323272. [Epub ahead of print]. An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report. Wu PW et al. Medicine (Baltimore). 2017 Jun;96(25):e7277. doi: 10.1097/MD.0000000000007277. Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation. Ragbourne SC et al. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):340-346.…

Complications of myeloma and its treatments

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Jakubowiak AJ et al. Hematology. 2017 May 25:1-7. doi: 10.1080/10245332.2017.1328165. [Epub ahead of print]. Clinical conditions responsible for hyperviscosity and skin ulcers complications. Caimi G et al. Clin Hemorheol Microcirc. 2017 May 19. doi: 10.3233/CH-160218. [Epub ahead of print]. Increased risk of arterial thromboembolic events with combination…

Complications of myeloma and its treatments

Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Lee SE et al. Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000506. [Epub ahead of print]. Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. Law LY et al. Mult Scler Relat Disord. 2017 Apr;13:21-24. doi: 10.1016/j.msard.2017.01.013. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD):…

Complications of myeloma and its treatments

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print]. Long-term control of extensive refractory chronic…

Complications of myeloma and its treatments

Renal failure in multiple myeloma: something new on the horizon. Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print]. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print]. Myelosuppression-sparing treatment of central nervous…

Complications of myeloma and its treatments

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Snowden JA et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14514. [Epub ahead of print]. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Beijers AJ et al. Ann Hematol. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead…

Complications of myeloma and its treatments

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…

Complications of myeloma and its treatments

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients. Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print]. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print]. Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors. Jouni H et al. Am J…

Complications of myeloma and its treatments

Management of gynaecologic plasmacytoma: A review article. Feldman AM et al. J Obstet Gynaecol. 2016 Oct 19:1-6. [Epub ahead of print]. Current treatments for renal failure due to multiple myeloma. Gavriatopoulou M et al. Expert Opin Pharmacother. 2016 Nov;17(16):2165-2177. Epub 2016 Sep 27. Comparative Confocal and Histopathological Study of Corneal Changes in Multiple Myeloma. Micali A et al. Cornea. 2016 Oct 5. [Epub ahead of print].…